Zobrazeno 1 - 10
of 105
pro vyhledávání: '"Volpicelli, A."'
Autor:
Joseph R. Volpicelli, Monica Casale, Charles P. O'Brien, Michael F. Stromberg, Laura A. Volpicelli
Publikováno v:
Alcohol. 15:281-289
The effects of the universal opioid antagonist naltrexone were compared to the delta-selective opioid antagonist naltrindole and the mu-selective opioid antagonist beta-funaltrexamine on ethanol consumption in the absence of food or fluid deprivation
Autor:
Peter Gariti, Thomas R. Ten Have, William D. Dundon, Kevin G. Lynch, Charles A. Dackis, Lois A. Gelfand, Charles P. O'Brien, Joseph R. Volpicelli, Shoshana M Wortman, David W. Oslin, Helen M. Pettinati, Kyle M. Kampman
Publikováno v:
Alcoholism: Clinical and Experimental Research. 32:1299-1308
There continues to be a need to develop better treatment models for alcohol dependence as evidenced by the relatively low rates of access to treatments found in epidemiological studies (Grant et al., 2004). The Institute of Medicine has suggested tha
Autor:
Joseph R. Volpicelli, Miriam C. Fenton
Publikováno v:
Future Neurology. 1:389-398
Naltrexone, an opioid receptor antagonist, is effective in the treatment of alcohol and opioid dependence. An important limitation of the use of oral naltrexone is the lack of efficacy among patients who do not consistently take the medication. The a
Publikováno v:
Psychopharmacology. 1997, Vol. 129 Issue 1, p15. 8p.
Autor:
Volpicelli, Joseph R., Clay, Karen L.
Publikováno v:
Alcohol Health & Research World. 1994, Vol. 18 Issue 4, p272. 7p. 1 Diagram, 1 Chart, 4 Graphs.
Autor:
David W. Oslin, Wade H. Berrettini, Helen M. Pettinati, Henry R. Kranzler, Joseph R. Volpicelli, Charles P. O'Brien, Joel Gelernter
Publikováno v:
Neuropsychopharmacology. 28:1546-1552
This study examined the association between two specific polymorphisms of the gene encoding the mu-opioid receptor and treatment outcomes in alcohol-dependent patients who were prescribed naltrexone or placebo. A total of 82 patients (71 of European
Publikováno v:
The American Journal of Geriatric Psychiatry. 10:740-747
Objective Adherence to treatment has been demonstrated to be an important factor for remission from alcohol dependence. The authors compared therapy and medication adherence for treatment of alcohol dependence in older adults with adherence in younge
Publikováno v:
Alcohol. 23:109-116
Both acamprosate and naltrexone have demonstrated clinical utility in reducing relapse to alcohol use in recovering alcoholics. The present experiments examined the effects of acamprosate and naltrexone, either alone or in combination, on basal ethan
Autor:
Helen M. Pettinati, John Monterosso, Charles P. O'Brien, Barbara A. Flannery, Margaret Rukstalis, David W. Oslin, Joseph R. Volpicelli
Publikováno v:
American Journal on Addictions. 10:258-268
Naltrexone has repeatedly been shown to reduce drinking in alcohol-dependent patients. Previous clinical research suggests that naltrexone may be more effective at reducing drinking among patients with high levels of alcohol craving at the beginning
Publikováno v:
Alcoholism: Clinical and Experimental Research. 24:1593-1596
Background: In humans, 6-β-naltrexol is the major metabolite of naltrexone, and its effectiveness at suppressing alcohol consumption in any species has not been previously investigated. Naltrexone is an opiate antagonist that reduces excessive drink